Acumen Pharmaceuticals Inc (ABOS) — Tangible Net Worth Ratio
Acumen Pharmaceuticals Inc (ABOS) has a Tangible Net Worth Ratio of 100.0% as of March 2026. This metric is calculated by deducting intangible assets ($24.00K) from net assets ($87.48 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Acumen Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Acumen Pharmaceuticals Inc Tangible Net Worth Ratio (2021–2025)
This chart shows how Acumen Pharmaceuticals Inc's Tangible Net Worth Ratio has changed across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 100.0%, reflecting net assets of $87.48 Million with intangible assets of $24.00K USD. Also explore net asset growth rate of Acumen Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Acumen Pharmaceuticals Inc (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Acumen Pharmaceuticals Inc from 2021 to 2025, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Acumen Pharmaceuticals Inc market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | $70.43 Million | $29.00K | $122.83 Million | ▲ +0.0 pp |
| 2024 | 100.0% | $181.82 Million | $75.00K | $238.99 Million | ▲ +0.0 pp |
| 2023 | 99.9% | $266.97 Million | $169.00K | $310.12 Million | ▼ -0.1 pp |
| 2022 | 100.0% | $188.78 Million | $0.00 | $196.59 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $225.18 Million | $0.00 | $230.33 Million | — |